PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsKanamycin
Kanamycin
Kantrex, Klebcil (kanamycin) is a small molecule pharmaceutical. Kanamycin was first approved as Kantrex on 1982-01-01. It is used to treat acinetobacter infections, bacterial infections, escherichia coli infections, hepatic encephalopathy, and klebsiella infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
nervous system diseasesD009422
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
respiratory tract infections—D012141J06.9
bacterial infections—D001424A49
escherichia coli infectionsEFO_1001318D004927B96.20
staphylococcal infections—D013203A49.01
hepatic encephalopathy—D006501K72.91
proteus infectionsEFO_1001130D011512—
acinetobacter infectionsEFO_1000792D000151—
klebsiella infectionsEFO_1001353D007710—
mycobacterium infections—D009164A31.9
serratia infectionsEFO_1001421D016868—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA08: Kanamycin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01G: Aminoglycoside antibacterials
— J01GB: Other aminoglycosides in atc
— J01GB04: Kanamycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA24: Kanamycin
HCPCS
Code
Description
J1840
Injection, kanamycin sulfate, up to 500 mg
J1850
Injection, kanamycin sulfate, up to 75 mg
Clinical
Clinical Trials
132 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ocular hypertensionD009798EFO_1001069H40.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameKanamycin
INNkanamycin
Description
Kanamycin A is a member of kanamycins. It has a role as a bacterial metabolite. It is a conjugate base of a kanamycin A(4+).
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
Identifiers
PDB—
CAS-ID59-01-8
RxCUI—
ChEMBL IDCHEMBL1384
ChEBI ID17630
PubChem CID6032
DrugBankDB01172
UNII IDRUC37XUP2P (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 30,704 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
303 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use